- Home
- RDCM vs NYXH Comparison
RDCM vs NYXH Comparison
Compare RDCM & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | NYXH |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | Israel | Belgium |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.2M | 188.1M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDCM | NYXH |
|---|---|---|
| Price | $13.41 | $4.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $18.00 | $12.67 |
| AVG Volume (30 Days) | ★ 76.8K | 41.8K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.57 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $68,901,000.00 | $6,616,215.00 |
| Revenue This Year | $18.86 | $79.25 |
| Revenue Next Year | $11.39 | $297.08 |
| P/E Ratio | $20.99 | ★ N/A |
| Revenue Growth | ★ 17.27 | 10.96 |
| 52 Week Low | $9.88 | $4.35 |
| 52 Week High | $15.98 | $11.87 |
Technical Indicators
Market Signals| Indicator | RDCM | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 48.89 |
| Support Level | $12.81 | $4.69 |
| Resistance Level | $13.88 | $4.93 |
| Average True Range (ATR) | 0.41 | 0.18 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 62.06 | 56.82 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.